Common Pitfalls in Local Pharmacovigilance and How to Avoid Them

Local pharmacovigilance plays an important role in ensuring patient safety at the country level. Since the work is fast-paced and highly regulated, even small mistakes can lead to compliance issues. In this article you will find some of common challenges local PV teams face and tips to prevent them.

Incomplete, Missing or Outdated Documentation

Local PV teams typically produce extensive documentation, such as literature search records, case logs, safety-related communications, educational materials, and correspondence with NCAs. One of the major risks is that some of these documents may be incomplete, missing, or not updated on time. This can lead to confusion within the team, delayed actions, or findings during audits.

Tips:

• Maintain clear and well-organized documentation processes.
• Regularly review local pharmacovigilance records for completeness and accuracy.
• Ensure that procedures, training records, and safety-related documentation are updated when changes occur.
• Establish appropriate document retention and archiving practices.

Delayed or Incomplete Adverse Event Reporting

Timely reporting of adverse events is one of the most important pharmacovigilance obligations. Delays in identifying, escalating, or forwarding safety information may result in non-compliance with regulatory reporting requirements.

Tips:

• Create an easy and clear reporting flow, including visual guides and quick reference sheets.
• Provide regular PV training to employees and relevant stakeholders focusing on what must be reported and how quickly.
• Ensure that all potential safety information is assessed promptly.
• Monitor compliance with reporting timelines through periodic oversight activities.

Ineffective Local Literature Monitoring

Local medical and scientific literature can be an important source of safety information. Inadequate literature monitoring may result in missed safety cases or delayed identification of emerging risks

Tips:

• Implement a structured approach to literature screening.
• Maintain documented search strategies and review processes.
• Ensure that potentially relevant findings are evaluated appropriately.
• Consider technology-enabled solutions to support efficiency while maintaining qualified human oversight.

Insufficient Oversight of Regulatory Intelligence

Keeping pace with evolving pharmacovigilance requirements and health authority expectations is critical for maintaining compliance. A lack of effective regulatory intelligence processes can result in gaps in implementation, inspection findings, and delayed action on important safety updates.

Tips:

• Establish a process for monitoring regulatory updates.
• Assess the impact of new requirements on existing pharmacovigilance activities.
• Update procedures and processes as necessary.
• Ensure relevant personnel remain informed through continuous training and communication.

Limited Business Continuity and Local PV Oversight

A robust local pharmacovigilance function is critical for ensuring timely management of safety information and compliance with regulatory obligations. Without effective LPPV and deputy LPPV support, organizations may face delays in responding to safety-related matters and challenges in maintaining business continuity during periods of staff absence.

Tips:

• Maintain clearly defined roles and responsibilities.
• Ensure appropriate delegation and backup arrangements are in place.
• Facilitate knowledge sharing among qualified personnel.
• Periodically review resource allocation to support sustainable operations.

Insufficient Oversight of Third-Party Service Providers

Many pharmaceutical companies rely on distributors, vendors, and service providers to support local activities. Without appropriate oversight, important safety information may be delayed, missed, or processed inconsistently.

Tips:

• Define responsibilities through appropriate pharmacovigilance agreements.
• Ensure third parties understand their safety reporting obligations.
• Conduct periodic compliance reviews and performance monitoring.
• Provide relevant pharmacovigilance training when required.

Local PV teams play a critical role in ensuring safe usage of medicinal products in every country. Most problems arise from missed information, unclear processes or lack of regular updates. With strong documentation habits, improved AE reporting routines, smarter literature monitoring, clear regulatory intelligence tracking and solid backup support for the LPPV, local PV teams can work more confidently and stay fully compliant.

At Insuvia, we support pharmaceutical companies with flexible local pharmacovigilance solutions designed to help maintain compliance, ensure operational continuity, and meet evolving regulatory expectations.